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TNF receptor-associated factor 2 (TRAF2) is a key intracellular sig-
naling mediator that acts downstream of not only TNFα but also
various members of the TNFα superfamily. Here, we report that,
despite their lack of TNFα signaling, TRAF2−/−TNFα−/− mice de-
velop an inflammatory disorder characterized by autoantibody
accumulation and organ infiltration by T cells with the phenotypes
of activated, effector, and memory cells. RAG1−/− mice reconsti-
tuted with TRAF2−/−TNFα−/− bone marrow cells showed increased
numbers of hyperactive T cells and rapidly developed progressive
and eventually lethal inflammation. No inflammation was ob-
served in RAG1−/− mice reconstituted with TRAF2−/−TNFα−/−T-cell
receptor β−/− or TRAF2−/−TNFα−/−NFκB-induced kinase+/− bone
marrow cells. The pathogenic TRAF2−/−TNFα−/− T cells showed
constitutive NFκB2p52 activation and produced elevated levels
of T-helper 1 and T-helper 17 cytokines. Our results suggest that
a regulatory circuit consisting of TRAF2–NFκB-induced kinase–
NFκB2p52 is essential for the proper control of effector T-cell po-
larization and that loss of T-cell TRAF2 function induces constitu-
tive NFκB2p52 activity that drives fatal autoimmune inflammation
independently of TNFα signaling. The involvement of this regula-
tory circuit in controlling autoimmune responses highlights the
delicate balance required to avoid paradoxical adverse events
when implementing new targeted anti-inflammatory therapies.
TNF receptor-associated factor 2 (TRAF2) is an importantadaptor protein and an E3 ubiquitin ligase. Our previous
studies of TRAF2-deficient mice showed that TRAF2 is essential
for mediating cell survival, normal adaptive immune responses,
and lymphocyte homeostasis (1, 2). We previously generated
TRAF2−/−TNFα−/− double knockout (DKO) mice and demon-
strated that the survival of TRAF2-deficient mice is greatly im-
proved by eliminating TNFα signaling (1, 2). Unexpectedly,
many TRAF2−/−TNFα−/− mice manifest an inflammatory phe-
notype as they age. We therefore postulated that TRAF2 de-
ficiency may either disrupt or derepress harmful signaling
pathways that operate independently of TNFα, such as non-
canonical NFκB2(p100/p52) signaling that spontaneously indu-
ces chronic inflammation (3).
Previously, Grech et al. demonstrated that B-cell–specific
TRAF2 KO mice showed increased B-cell survival concomitant
with constitutive NFκB2 activation (4). Another study, by Gar-
dam et al., showed that TRAF2 and TRAF3 coordinate and
negatively regulate B-cell–activating factor of the TNF family
(BAFF) signaling in B cells, suggesting that TRAF proteins may
cooperate to control signaling downstream of TNF receptor
superfamily members (5). More recent studies have linked
TRAF2 and TRAF3 to the control of NFκB-induced kinase
(NIK), which regulates the processing of NFκB2p100 to NFκB2p52
(6, 7). Studies of NIK-deficient mice have also supported the
notion that the p100 form of NFκB2 can serve as a negative
feedback regulator for the classical NFκB1 signaling pathway
triggered during T-cell receptor (TCR)-mediated T-cell activa-
tion (8). Interestingly, NIK-deficient mice are prone to autoim-
munity because of a defect in the production of regulatory T
cells (9). In addition, transgenic mice constitutively expressing
NFκB2p52 in lymphocytes develop inflammatory autoimmune
disease (3). These results indicate that the threshold of NFκB2
signaling must be properly controlled to keep the immune system
in check and that TRAF2 appears to be a key player in this
complex regulatory circuit.
In this study, we found that the constitutive NFκB2 activity
resulting from TRAF2 ablation led to aberrant T-cell activation
and a skewing toward T-helper 1 (Th1)/Th17 effector T-cell
polarization that accounted for the autoimmune inflammatory
response. Moreover, this phenotype could be reversed by a hap-
lodeficiency of NIK. Our results show that a delicate balance of
TRAF2/NIK/NFκB2 signaling controls T-cell inflammatory
responses independently of TNFα and that proper manipulation
of this balance will be needed to achieve effective new treat-
ments for autoimmune and chronic inflammatory disorders.
Results
TRAF2 Deficiency Results in Chronic Inflammation and a Defect in
Peripheral T-Cell Tolerance Independent of TNFα Signaling.TRAF2−/−
TNFα−/− (DKO) mice were born at less than the expected
Mendelian ratio (Table S1), and many of the survivors had ab-
normally short life spans (Fig. 1A). Some of these DKO mice
showed the small body size, ruffled fur, and wasted appearance
that is often associated with chronic inflammation. Histological
examination of these animals at age 6 wk revealed significant
lymphocyte infiltration into the lungs and liver (Fig. 1B and Fig.
S1A). At about 6 months of age, several DKO mice manifested
distension of the abdominal cavity and eye inflammation (Fig.
S1B), confirming that the chronic inflammation persists and
increases in intensity as the mice age. Serum anti-dsDNA and
anti-histone antibodies were increased in DKO mice (Fig. S2).
These data suggested that, even in the absence of TNFα signaling,
TRAF2 deficiency leads to chronic inflammation and defects in
immune tolerance that eventually compromise viability.
Examination of T-cell subsets among the peripheral lympho-
cytes from DKO mice and littermate controls by flow cytometry
(FACS) revealed that the effector/memory (CD44hiCD62Llo)
and activated (CD69+) populations among total lymph node
Author contributions: W.-J.L. and T.W.M. designed research; W.-J.L., Y.-W.S., Y.-C.L., Z.H.,
I.I.C.C., N.-J.C., A.B., and W.Y.L. performed research; T.W.M. contributed new reagents/
analytic tools; W.-J.L. and Y.-W.S. analyzed data; and W.-J.L. and T.W.M. wrote the paper.
The authors declare no conflict of interest.
This article is a PNAS Direct Submission.
Freely available online through the PNAS open access option.
1To whom correspondence should be addressed. E-mail: tmak@uhnres.utoronto.ca.
This article contains supporting information online at www.pnas.org/lookup/suppl/doi:10.
1073/pnas.1109427108/-/DCSupplemental.
18354–18359 | PNAS | November 8, 2011 | vol. 108 | no. 45 www.pnas.org/cgi/doi/10.1073/pnas.1109427108
(LN) and lung DKO CD4+ T cells were markedly increased (Fig.
1C). Analysis of serum cytokines showed that DKO mice had
elevated levels of IL-1, IL-2, IL-6, IL-12, IL-17, and IFNγ (Fig.
S3). Altogether, the combined presence in DKO mice of in-
creased activated-, effector-, and memory-type T cells, elevated
serum autoantibodies, and up-regulated Th1 and Th17 cytokines
suggests that these mutants suffer from a breakdown in T-cell
tolerance. These data thus demonstrate a previously un-
recognized role for TRAF2 as an immune tolerance regulator
that acts independently of the TNFα pathway to help prevent
severe inflammatory disease.
TRAF2 Function in T Cells Is Required to Prevent Autoimmune
Inflammation. To determine whether the inflammatory pheno-
type of DKO mice resulted from an intrinsic defect in immune
cells originating from hematopoietic stem cells, we generated
RAG1−/− chimeric mice that were reconstituted with bone
marrow (BM) cells from DKO mice or their control littermates.
FACS analysis of peripheral lymphocytes from DKO chimeras
revealed significant increases in activated-, effector-, and memory-
type CD4+ T cells (Fig. S4A). Starting at 5 wk postreconstitution,
DKO chimeras developed diarrhea, hunched back, hair loss, and
ruffled coat (Fig. S4B), a constellation of features consistent with
the acute onset of progressive inflammatory disease. The chimeric
mutants showed a dramatic loss in weight by age 5 wk (Fig. 2A).
In contrast, mice reconstituted with control BM cells remained
healthy throughout the entire 8-wk observation period. At 4 wk
postreconstitution, we isolated the colons of some DKO chi-
meras and noted marked hemorrhaging and swelling indicative
of severe colitis (Fig. S4C). Histological analysis of surviving (but
sick) DKO chimeras at 6 wk postreconstitution revealed massive
mononuclear infiltrates in lung and colon (Fig. 2B). By 8 wk
postreconstitution, fully 90% of DKO chimeras were dead (Fig.
2C). To confirm that the aggressive inflammation in DKO chi-
meras was caused by an intrinsic T- or B-cell defect, we first
established DKO mice in the TCRβ−/− background and exam-
ined the phenotypes of RAG1−/− recipients reconstituted with
BM cells from DKO/TCRβ+/− or DKO/TCRβ−/− mice. Like
DKO chimeras, DKO/TCRβ+/− chimeras (T cells intact) showed
hunched back, rough fur, and reduced weight by 5 wk post-
reconstitution (Fig. S4D). In contrast, DKO/TCRβ−/− chimeras,
which lack functional T cells, remained healthy throughout the
entire observation period. Thus, the lethal inflammatory disease
in DKO chimeras truly depends on T cells.
Dysregulated NFκB2 Signaling and Cytokine Production in DKO T
Cells. To determine whether TRAF2 is a T-cell intrinsic regula-
tor, we first examined the expression pattern of TRAF2 in WT T
cells after TCR engagement and found that TRAF2 was strongly
induced in a time-dependent fashion by anti-CD3/CD28 anti-
body cross-linking (Fig. S5A). We then investigated the effect of
TRAF2 ablation on the canonical NFκB1 and noncanonical
NFκB2 signaling cascades in T cells. As expected, IκBα degra-
dation proceeded in the expected time-dependent fashion in
stimulated littermate control CD4+ T cells but was significantly
impaired in stimulated DKO CD4+ T cells (Fig. 3A). In addition,
nuclear RelA/p65 levels were dramatically decreased in DKO
CD4+ T cells after anti-CD3/CD28 stimulation (Fig. S5B). In
contrast, components of the noncanonical NFκB2 signaling
pathway (p52 and RelB) were increased in DKO CD4+ T cells
(Fig. S5B). Consistently, DKO CD4+ T cells exhibited increased
NFκB2p100 processing even in the absence of exogenous TCR
stimulation (Fig. 3A). Thus, we postulate that the constitutive
processing of NFκB2p100 in DKO CD4+ T cells may be the
major driving signal that forces the expansion of activated-, ef-
fector-, and memory-like T cells.
To determine the effects of TRAF2 loss on cytokine expres-
sion induced by TCR engagement, we examined intracellular
cytokine production in isolated DKO and littermate control
CD4+ T cells treated with phorbol myristate acetate (PMA)/
ionomycin in vitro. At 4 h after PMA/ionomycin stimulation,
significant increases in the percentages of IL-17+ (2.42%) and
IFNγ+ (1.88%) subsets were observed among stimulated DKO
CD4+ T cells (Fig. 3B). Interestingly, marked increases in the
percentages of IL-17+ and IFNγ+ cells were also observed
among unstimulated DKO CD4+ T cells (Fig. 3B), an abnor-
mality that likely contributes to the progressive inflammation
observed in DKO mice. Similarly, IL-2 mRNA was already
greatly increased in DKO CD4+ T cells compared with controls
before anti-CD3/CD28 stimulation (Fig. S5C). However, isolated
DKO CD4+ T cells stimulated with anti-CD3/CD28 showed
impaired, rather than enhanced, TCR-induced T-cell pro-
BA
C Fig. 1. Development of fatal inflammatory disease in
TRAF2−/−TNFα−/− (DKO) mice. (A) Reduced survival. TRAF2−/−
TNFα−/− (DKO) and TRAF2+/−TNFα−/− (littermate control)
mice were monitored for survival for over 1 y. Results are
expressed as the percentage of original mice remaining vi-
able. (B) Lymphocyte infiltration. Lung sections from 4-mo-
old DKO and control mice were stained with H&E to show
gross structure (Left), with anti-B220 to detect B cells (Cen-
ter), and with anti-CD3 to detect T cells (Right). (Scale bar
applies to all images.) (C) Flow cytometric determination of
surface expression of CD44, CD62L, and CD69 proteins on T-
cell subsets from LN and lungs of DKO and TRAF2+/−TNFα−/−
(littermate control) mice. Numbers in quadrants indicate the
percentage of total CD4+ T cells represented by the subset
of interest. For B and C, data shown are representative of at
least five independent experiments.
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liferation (Fig. S5D). Altogether, these data suggest that the loss
of TRAF2 in DKO CD4+ T cells impairs canonical NFκB1 sig-
naling but constitutively activates noncanonical NFκB2 signaling.
Next, we used quantitative real-time PCR (qPCR) to examine
the mRNA expression of a broad range of cytokines by DKO and
control CD4+ T cells. As expected, there was a significant increase
in DKO CD4+ T cells in the basal expression of several cytokine
mRNAs, including IFNγ, IL-17, IL-21, and IP-10 (Fig. 3C). Upon
anti-CD3/CD28 stimulation, levels of IFNγ, IL-17, and IL-21
mRNAs in DKO CD4+ T cells were greatly enhanced compared
with stimulated control T cells (Fig. 3C). More importantly, this
robust induction of IL-21mRNA inDKOCD4+T cells, regardless
of stimulation, identified these cells as activated inflammatory
lymphocytes, consistent with the previous identification of IL-21 as
crucial for the development of various inflammatory diseases (10).
Thus, our data suggest that the constitutive NFκB2p100/p52 pro-
cessing in DKO T cells drives the overexpression of inflammatory
cytokines such as IL-17, IFNγ, and IL-21 that skew T-cell differ-
entiation toward Th1/Th17 polarization.
TRAF2 Is Required for Controlling NFκB2-Mediated Regulation of
Naïve and Effector T-Cell Functions. The production of proin-
flammatory cytokines by DKO T cells suggested that loss of
TRAF2 has a profound impact on effector T-cell function. We
then analyzed TRAF2 and NFκB2 expression in sorted WT
(C57BL/6 TRAF2+/+TNFα+/+) naïve (CD4+CD62Lhi) and ef-
fector (CD4+CD62Llo) T cells. Immunoblotting revealed that
TRAF2 protein was comparable in WT naïve and effector T cells
but that NFκB2p100, NFκB2p52, and RelB were all increased in
WT effector cells compared with WT naïve cells (Fig. S6). These
data imply that proper NFκB2 signaling is required for normal T-
cell activation and effector-cell differentiation. Interestingly, the
RelB and NFκB2p52 proteins were substantially increased in
both DKO naïve and effector T cells compared with control
T cells (which exhibited the WT pattern) (Fig. 4A). This dra-
matic and aberrant increase in NFκB2 protein in naïve DKO T
cells suggested that they may have undergone premature dif-
ferentiation into effector T cells, consistent with our FACS data.
Surprisingly, the Bim and Bcl-XL proteins were also strikingly
elevated in these naïve DKO CD4+ T cells (Fig. 4A), a relevant
finding because Bim was unexpectedly shown to be required for
the activation of autoreactive T cells (11). We speculate that the
excessive NFκB2 activation and increased levels of Bim and Bcl-
XL in unstimulated DKO T cells lead to their premature ac-
quisition of activated (effector) status, promoting the production
of Th1 and Th17 cytokines and autoimmune inflammation.
The transcription factor IFN regulatory factor 4 (IRF4) is
essential for IL-21 production and Th17 cell differentiation (12,
13). We therefore examined IRF4 expression in DKO and
control naïve and effector T cells. Compared with control ef-
fector T cells, DKO effector T cells showed much higher levels of
IRF4 expression, in parallel with their aberrant increase of
NFκB2 (Fig. 4A). Furthermore, levels of IL-21, RORγt, and IL-
17 mRNAs were significantly increased in both DKO naïve and
effector T cells (Fig. 4B). The altered expression of NFκB2 in
DKO naïve T cells combined with the marked increases in IL-21,
RORγt, and IL-17 mRNAs support a scenario in which aberrant
activation of NFκB2 signaling caused by loss of TRAF2 triggers
the up-regulation of Th17-related genes that drive the premature
differentiation of inflammatory (effector) T cells and the de-
velopment of autoimmune symptoms.
Inflammatory Disorder in DKO Chimeric Mice Is NFκB2-Dependent.
Previous studies have clearly demonstrated that the genetic de-
letion of one NIK allele in mice blocks the postnatal death in-
duced by TRAF2 ablation (6, 7). To determine whether TRAF2/
NIK/NFκB2 signaling was also important for the T-cell–de-
pendent inflammatory disorder in our DKO mice, we explored
BA
C
Fig. 2. RAG1−/− chimeras reconstituted with
TRAF2−/−TNFα−/− BM cells recapitulate the phe-
notypes of DKOmice. (A) Decreased body weight.
The body weights of the TRAF2−/−TNFα−/−RAG1−/−
chimeric mice (DKO chimeras) and TRAF2+/−
TNFα−/−RAG1−/− littermate control chimeric mice
were monitored weekly starting at 1 wk post-
reconstitution. Data are mean mouse body
weight ± SD expressed as a percentage of the
original mean weight at week 0. *P < 0.05.
Results shown are from a single experiment in-
volving 15–16mice per genotype. (B) Lymphocyte
infiltration. Lung and colon sections from DKO
chimeras and controls (n = 5 per group) were
examined histologically at 6 wk postreconsti-
tution. Lungs and colon were stained with H&E
to show gross structures. Colons were immunos-
tained with anti-CD3 to detect T cells and with
anti-Ki67 to detect damage-induced epithelial
proliferation. (Scale bars apply to all images.)
Data shown are representative of two indepen-
dent experiments. (C) Decreased survival. The
survival of the chimeric mice in A was monitored
weekly starting at 1 wk postreconstitution. Data
are percentage survival. *P < 0.05.
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the role of NIK in the phenotypes of our DKO mice and DKO/
RAG1−/− chimeras. We first attempted to breed TRAF2+/− mice
with NIK+/− animals (Map3k14+/− in a pure C57B/6 back-
ground), but no viable TRAF2−/−NIK+/− or TRAF2−/−NIK−/−
mice were produced over a 2-y observation period. However, we
were successful in intercrossing TRAF2+/−NIK+/−TNFα−/− mice
to generate TRAF2−/−NIK+/−TNFα−/− (DKO/NIK+/−) mice
and TRAF2−/−NIK−/−TNFα−/− (TKO) mice. Although DKO/
NIK+/− mice remained healthy and did not manifest any de-
velopmental abnormalities (Fig. 5Aa and Fig. S7), the TKO
mutants were sickly from birth and rapidly developed alopecia,
hunched back, and psoriasis-like skin inflammation (Fig. 5Ab
and Fig. S7). Histological analysis revealed heavy infiltration of
mononuclear cells into multiple organs of TKO mutants, in-
cluding skin (Fig. 5Ad) and lung (Fig. 5Bd). The TKO mice
eventually developed autoimmune symptoms and died within
8 wk. In contrast, histological analysis of skin and lung tissues
from DKO/NIK+/− mice revealed a normal phenotype with no
sign of the major inflammatory infiltrates observed in DKO and
TKO mice (Fig. 5 Ac and Bc). These data suggest that there is a
delicate balance of TRAF2/NIK/NFκB2 signaling that sustains
T-cell tolerance and that disruption of this balance in any way
can lead to the development of lethal autoimmune disease.
Analysis of lymphoid cell populations in DKO/NIK+/− mice
showed no differences in CD4+CD69+ and CD8+CD69+ T-cell
subsets compared with their TRAF2-expressing littermate
controls (Fig. S8A). Similarly, the ablation of one NIK allele
reduced the elevated expression of IFNγ and IL-17 that was
observed in DKO CD4+ T cells (Fig. S8B). Because NIK controls
the processing of NFκB2 (7), our results imply that the normal
phenotypes of DKO/NIK+/− mice result from the genetic atten-
uation of the aberrant NFκB2 activation induced by loss of
TRAF2. To further investigate the role of NIK ablation in pre-
venting lethal inflammation, we reconstituted RAG1−/−mice with
BM cells from TRAF2+/−TNFα−/−, TRAF2−/−TNFα−/− (DKO),
TRAF2+/−NIK+/−TNFα−/−, or TRAF2−/−NIK+/−TNFα−/− (DKO/
NIK+/−) mice. Consistent with our previous observations, DKO
chimeras quickly exhibited a hunched back, weight loss, alopecia,
and diarrhea. In contrast, DKO/NIK+/− chimeras remained healthy
and did not develop any inflammatory symptoms during the en-
tire 6-mo observation period (Fig. 5C). Thus, the fatal inflam-
mation induced by loss of TRAF2 is indeed attributable to
dysregulation of the NFκB2 signaling pathway. Our observations
expose a vital function of TRAF2 in balancing NFκB2 signaling
in T cells for preventing fatal autoimmune inflammation.
Discussion
We previously demonstrated that TNFα deficiency significantly
increases the survival rate of TRAF2 KO mice, although it is
unable to prevent the development of chronic inflammation in
these mutants. Our current work with reconstituted DKO chi-
meras has shown that the rapid onset of lethal inflammatory
disease is intrinsic to hematopoietic cells. Our crosses to TCRβ−/−
mice have established that elimination of DKO T cells prevents
this inflammation, directly linking DKO T cells to the autoim-
mune phenotype. These results therefore clearly distinguish be-
A
C
B
Fig. 3. TRAF2 regulates TCR downstream
signaling and cytokine expression in T cells.
(A) Impaired IκBα degradation and in-
creased NFκB2p100 processing. CD4+ T cells
were isolated from DKO and control litter-
mate mice and stimulated in vitro with anti-
CD3/CD28 for the indicated times. Lysates
were immunoblotted to detect expression
levels of IκBα, phosphorylated forms of
ERK1/2 (p-ERK1/2) and JNK1/2 (p-JNK1/2),
NFκB2p100, and NFκB2p52 proteins. Actin
was used as loading control. (B) Increased
Th1 and Th17 cells. DKO and control CD4+ T
cells were stimulated in vitro with PMA/
ionomycin, and levels of intracellular IFNγ
and IL-17 expression were analyzed by flow
cytometry. (C) Increased inflammatory cy-
tokine mRNA expression. DKO and control
CD4+ T cells were stimulated for 12 h with 0,
5, or 10 μg/mL anti-CD3/CD28, and levels of
IFNγ, IL-17, IL-21, and IP-10 mRNAs were
determined by qPCR. Data shown are the
mean ± SD of triplicates and are expressed
as fold increase relative to 18S RNA. All
results shown are representative of three
independent experiments.
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tween the functions of TRAF2 and its related family member
TRAF3 in suppressing autoimmune inflammatory responses and
show that distinct immune cell types are involved (14). For ex-
ample, a previous study demonstrated that TRAF2 KO mice
showed an expansion of marginal-zone B cells but decreased
splenic B cells (6, 7). However, this study did not comment on
whether these animals showed any signs of inflammatory disease.
Interestingly, a study of B-cell–specific TRAF3 KO mice showed
that the mutants exhibited splenomegaly and expanded marginal-
zone B cells with increased NFκB2 activity (14). As they aged,
these B-cell–specific TRAF3 KOmice developed an autoimmune
disease characterized by increased anti-dsDNA antibodies and
immune complex deposition in the kidney. Thus, activated
TRAF3-deficient B cells alone can initiate the development of an
autoimmune disease that is most likely driven by the constitutive
NFκB2 activation. Interestingly, the early death induced by loss
of either TRAF2 or TRAF3 can be prevented by deleting one
NIK allele (6, 7), implying that constitutive activation of the
noncanonical NFκB2 pathway is the main driver of the postnatal
deaths of TRAF2 KO and TRAF3 KO mice. Also, the in-
flammatory phenotypes of DKO mice and DKO chimeras can be
rescued by ablating one NIK allele. Thus, our results are con-
sistent with previous reports and firmly establish that TRAF2 is
an essential and direct negative regulator of the NFκB2 pathway.
At the cellular level, we found that TRAF2 is up-regulated in WT
CD4+ T cells in response to TCR engagement (Fig. S5A), sug-
gesting that TRAF2 has a T-cell–intrinsic role in the maintenance
of immune homeostasis. Numbers of memory- and effector-type
cells were increased among DKO CD4+ T cells (Fig. 1C), cor-
relating with the enhanced NFκB2p52 processing observed in
total DKO CD4+ T cells (Fig. 3A). Thus, the dysregulated
NFκB2 signaling in DKO mice may push T cells over the limit of
peripheral tolerance control and result in chronic inflammation.
Our results also showed that NFκB1 signaling downstream of
TCR engagement was significantly impaired in DKO CD4+ T
cells (Fig. 3A and Fig. S5B). This contrasting effect of TRAF2
deficiency on the canonical and noncanonical NFκB pathways
leads us to propose that the NFκB2 pathway is abnormally
dominant over NFκB1 signaling in DKO CD4+ T cells and that a
crucial function of TRAF2 in WT T cells is to direct signals ini-
tiated by TCR engagement first into the NFκB1 pathway and then
into the NFκB2 pathway. This hypothesis is supported by a pre-
vious report demonstrating the sequential involvement of NFκB1
and NFκB2 in the regulation of TCR activation (8). Our results
A B
Fig. 4. Molecular impact of TRAF2 deficiency on
CD4+CD62Lhi and CD4+CD62Llo T cells. (A) Increased
IRF4 and NFκB2 in DKO T cells. DKO and TRAF2+/−
TNFα−/− (littermate control) CD4+CD62Lhi and CD4+
CD62Llo T cells were immunoblotted to detect the
indicated proteins. (B) TRAF2 deficiency augments
Th17-related gene expression. DKO and littermate
control CD4+CD62Lhi and CD4+CD62Llo T cells were
subjected to qPCR to detect expression levels of
IL-17, IL-21, and RORγ mRNAs as described in Fig.
3C. All results shown are representative of two in-
dependent experiments.
A
C
B
Fig. 5. Deletion of one NIK allele ameliorates inflammatory disease in DKO
mice and DKO chimeras. (A) Comparison of DKO and TKOmice. (Upper) Gross
appearance. (Lower) H&E staining of mouse skin. TKO mice (b and d) exhib-
ited psoriasis-like inflammation in the skin that was absent from DKO/NIK+/−
mice (a and c). (B) Lymphocyte infiltration. Lung sections from TRAF2+/−
NIK+/+TNFα−/− (a), TRAF2−/−NIK+/+TNFα−/− (b), TRAF2−/−NIK+/−TNFα−/− (DKO/
NIK+/−) (c), and TRAF2−/−NIK−/−TNFα−/− (TKO) (d) mice were stained with H&E
and examined for the presence of lymphocytes. (Scale bar applies to all
images.) For A and B, results shown are representative of two independent
experiments involving three mice per group. (C) RAG1−/− mice were recon-
stituted with BM cells from mice of the indicated genotypes (n = 5 per
group). Mouse body weights were monitored weekly for 8 wk after re-
constitution. DKO/NIK+/− chimeras showed no weight loss or inflammation.
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also identify TRAF2 as a unique “gatekeeper” of NFκB signaling
downstream of TCR activation. For example, both TRAF6 and
TRAF2 are major mediators of the TCR/IκB kinase/NFκB1
pathway (15), and deficiency for TRAF6 or TRAF2 (Fig. 3A)
seriously impairs TCR-induced IκBα degradation (15). However,
unlike TRAF2, TRAF6 deficiency has not been directly linked to
NFκB2 signaling (16). Similarly, TRAF3 deficiency has no effect
on the NFκB1 pathway (17). Thus, TRAF2 appears to have a
distinct and vital position in regulating T-cell homeostasis via a
unique mechanism of control over NFκB1/2 signaling.
Interestingly, a particularly robust increase in IL-17, RORγt, and
IL-21 expression was observed in DKO CD4+CD62Lhi T cells (Fig.
4B), indicating that constitutive activation of NFκB2 in naïve DKO
T cells was sufficient to induce Th17 differentiation. Furthermore,
IL-21 is known to activate Th17-related gene expression in regula-
tory T cells, thereby eliminating the suppressive function of these
cells (18). We believe that the augmented IL-21 induction in our
DKO CD4+ T cells may have promoted Th17 differentiation while
suppressing regulatory T-cell function, thus driving inflammatory
disease development. Similarly, the expression of IRF4, which is
essential for IL-17 and IL-21 production, was markedly up-regu-
lated in DKO effector T cells (Fig. 4A). Our data in Fig. 4A confirm
previous work showing that the differentiation of naïveWTCD4+ T
cells into effectors requires increased NFκB2p52 activity (8) and
that the induction of IRF4 mRNA in nfkb1−/− lymphocytes stimu-
lated with anti-CD3/CD28 is normal (19). Because our results show
that IRF4 up-regulation in DKO effector T cells relies on the
NFκB2 pathway, they provide evidence of a previously unappre-
ciated link between NFκB2 signaling and Th17 differentiation.
We have established that the abnormal Th1/Th17 polarization
ofDKOeffector T cells depends onNFκB2 because the ablation of
one NIK allele in our DKO mice successfully prevented the de-
velopment of the autoimmune phenotype (Fig. 5C and Fig. S7).
Both the elevated expression of IFNγ and IL-17 and aberrant in-
flammation were rescued in DKO/NIK+/− mice and reconstituted
DKO/NIK+/−RAG1−/− chimeras (Fig. S8B). Thus, fine-tuned con-
trol of NFκB2 activation is vital not only for embryogenesis but also
for effector T-cell differentiation and the maintenance of immune
tolerance. Thus, we believe that TRAF2 has a unique and critical
role in preventing inflammatory disease development because it
blocks unnecessary NFκB2 activation in T cells and thereby heads
off deleterious expansion of Th1 and/or Th17 effector cells.
In summary, our DKO mice demonstrate that negative regu-
lation of the NIK/NFκB2 signaling pathway by TRAF2 is im-
portant for maintaining immune homeostasis. Despite TNFα
ablation, excessive NFκB2 activation in DKO mice enhanced T-
cell activation and triggered an autoimmune-like disease char-
acterized by increased Th1 and Th17 cells. Furthermore, the
inflammatory phenotype of DKO mice was rescued by deletion
of one NIK allele. Thus, TRAF2-mediated control of NIK/
NFκB2 signaling is important for both embryogenesis and pre-
venting harmful inflammation. The role identified for TRAF2 by
our findings may inspire the development of important new
strategies for treating or blocking autoimmune diseases.
Materials and Methods
Generation of DKO Mice. Homozygous TRAF2−/−TNFα−/− DKO mice were
generated by crossing TRAF2+/− and TNFα+/−mice as previously described (2).
NIK+/− mice were a kind gift from Amgen Inc. and were backcrossed to
C57BL/6 mice for six generations. TCRβ−/− and RAG1−/− mice were obtained
from The Jackson Laboratory. All mice were housed in the University Health
Network Mouse Facility under specific pathogen-free conditions. All mouse
procedures were approved by the University Health Network Institutional
Animal Care and Use Committee.
BM Chimeras. BM cells were isolated from DKO, DKO/NIK+/−, or DKO/TCRβ−/−
mice or their corresponding littermate controls. See SI Materials and
Methods for details.
Histology, Serum Cytokines, and Autoantibodies. Mouse blood and organs
were harvested for determination of cytokines and autoantibodies by ELISA
and histological examinations. See SI Materials and Methods for details.
Flow Cytometry and Intracellular Cytokines. For surface marker or cytokine
determinations, spleen and LN cells (1 × 106) were stained with antibodies
(BD Pharmingen) and subjected to flow cytometric analysis. See SI Materials
and Methods for details.
T-Cell Isolation and in Vitro Stimulation. Total CD4+, naïve CD4+CD62Lhi, and
effector CD4+CD62Llo T cells were isolated and stimulated as described in SI
Materials and Methods.
Immunoblotting and qPCR. Immunoblotting and qPCR were conducted as
described in SI Materials and Methods.
Statistical Analyses. The Student’s t test was used for most comparisons of
DKO and littermate control cells. The Wilcoxon rank-sum test was used to
compare levels of serum cytokines and autoantibodies. The log-rank test was
used for the statistical analysis of mouse survival. Values are expressed as the
mean ± SD, and P < 0.05 was considered statistically significant. Statistical
analyses and graphing were performed with GraphPad Prism software.
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